Clinical studies have reported that mutations in ARHGEF18 lead to increased susceptibility to nonidiopathic pulmonary hypertension associated with coronary artery disease (Li et al., 2018), and systematic knockdown of Arhgef18 results in embryonic death in mice (Beal et al., 2021). This evidence concerns the gene ARHGEF18 and pulmonary arterial hypertension.